Cervixcancer en klinisk utmaning
(2015) In Läkartidningen 112.- Abstract
Cervical cancer is the third most common female cancer world wide. In Sweden, some 450 cases are diagnosed annually. One out of three affected Swedish women is under the age of 40. Survival for all stages is 73 % in Sweden. Human papilloma virus (HPV) can be detected in the majority of all cervical cancers. Treatment consists of surgery for early stages, and a combination of chemoradiation and brachytherapy for locally advanced disease. For metastatic disease, the treatment is palliative. Late side effects after treatment may have serious impact on the quality of life. There is a strong need for more efficient treatment of metastatic disease. Current lines of research include surgical strategies, optimised radiotherapy, neoadjuvant... (More)
Cervical cancer is the third most common female cancer world wide. In Sweden, some 450 cases are diagnosed annually. One out of three affected Swedish women is under the age of 40. Survival for all stages is 73 % in Sweden. Human papilloma virus (HPV) can be detected in the majority of all cervical cancers. Treatment consists of surgery for early stages, and a combination of chemoradiation and brachytherapy for locally advanced disease. For metastatic disease, the treatment is palliative. Late side effects after treatment may have serious impact on the quality of life. There is a strong need for more efficient treatment of metastatic disease. Current lines of research include surgical strategies, optimised radiotherapy, neoadjuvant therapy, targeted therapy, and immunotherapy including therapeutic vaccines.
(Less)
- author
- Bjurberg, Maria LU ; Beskow, Catharina ; Kannisto, Päivi LU and Lindahl, Gabriel
- alternative title
- Cervical cancer is a clinical challenge
- publishing date
- 2015-12-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Läkartidningen
- volume
- 112
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:26646957
- scopus:84949557811
- ISSN
- 1652-7518
- language
- Swedish
- LU publication?
- no
- id
- d31adaae-72c8-4629-bdf2-be968e7a07ff
- date added to LUP
- 2016-07-13 12:20:23
- date last changed
- 2022-04-16 18:30:57
@article{d31adaae-72c8-4629-bdf2-be968e7a07ff, abstract = {{<p>Cervical cancer is the third most common female cancer world wide. In Sweden, some 450 cases are diagnosed annually. One out of three affected Swedish women is under the age of 40. Survival for all stages is 73 % in Sweden. Human papilloma virus (HPV) can be detected in the majority of all cervical cancers. Treatment consists of surgery for early stages, and a combination of chemoradiation and brachytherapy for locally advanced disease. For metastatic disease, the treatment is palliative. Late side effects after treatment may have serious impact on the quality of life. There is a strong need for more efficient treatment of metastatic disease. Current lines of research include surgical strategies, optimised radiotherapy, neoadjuvant therapy, targeted therapy, and immunotherapy including therapeutic vaccines. </p>}}, author = {{Bjurberg, Maria and Beskow, Catharina and Kannisto, Päivi and Lindahl, Gabriel}}, issn = {{1652-7518}}, language = {{swe}}, month = {{12}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Cervixcancer en klinisk utmaning}}, url = {{https://lup.lub.lu.se/search/files/9677108/8505363.pdf}}, volume = {{112}}, year = {{2015}}, }